Claudio Cerchione, MD, PhD, discusses the significance of the FDA approval of subcutaneous isatuximab in multiple myeloma.
Claudio Cerchione, MD, PhD
Advertisement
Articles by Claudio Cerchione, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
2
FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced Solid Tumors
3
Research Rewind: Phase 3 Breast Cancer Data Highlights From Q2 2026
4
Phosphorus-32 Plus FOLFIRINOX Meets Primary End Points in Locally Advanced Pancreatic Cancer
5